All In Biotech

Drug Trial Radar · NCT04690192

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

CNCT19 Following Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Aggressive B-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 1, 2021

Primary completion

Dec 30, 2023

Study completion Dec 30, 2024

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Juventas Cell Therapy Ltd.
First posted
Dec 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.

Conditions

  • Large B-cell Lymphoma

Interventions

  • CNCT19Biological

    2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion

  • Gemcitabine InjectionDrug

    600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,

  • busulfanDrug

    105mg/m2, day -7 until -5,

  • Melphalan InjectionDrug

    60mg/m2, day -3, -2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants experiencing adverse eventsTime frame: from the first day of high-dose chemotherapy until 2 years post CNCT19 infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.